PHASE I PK STUDY OF BMS-247550 IN ADVANCED MALIGNANCIES AND LIVER DYSFUNCTION

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究不再招募受试者。 (来自国家癌症研究所的PDQ？数据库的临床试验摘要) 化疗中使用的药物以不同的方式阻止肿瘤细胞分裂，从而停止生长或死亡。 这是一项研究BMS-247550治疗晚期实体瘤或淋巴瘤和肝功能障碍患者的I期试验。 患者将每3周接受一次3小时的BMS-247550输液。只要显示出益处，治疗就可以继续进行。患者将定期接受评估，为期1个月。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is no longer recruiting subjects. (Clinical trial summary from the National Cancer Institute's PDQ¿ database) Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. This is a Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid tumors or lymphomas and liver dysfunction. Patients will receive a 3-hour infusion of BMS-247550 every 3 weeks. Treatment may continue for as long as benefit is shown. Patients will be evaluated periodically for 1 month.